BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.840
+0.040 (2.22%)
May 12, 2025, 4:00 PM - Market closed
BioRestorative Therapies Revenue
In the year 2024, BioRestorative Therapies had annual revenue of $401.00K with 175.03% growth. BioRestorative Therapies had revenue of $43.30K in the quarter ending December 31, 2024, with 124.35% growth.
Revenue (ttm)
$401.00K
Revenue Growth
+175.03%
P/S Ratio
35.72
Revenue / Employee
$36,455
Employees
11
Market Cap
13.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 401.00K | 255.20K | 175.03% |
| Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
| Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
| Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
| Dec 31, 2020 | 77.00K | -53.00K | -40.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BRTX News
- 4 days ago - BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 - GlobeNewsWire
- 5 days ago - BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 - GlobeNewsWire
- 27 days ago - BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities - GlobeNewsWire
- 4 weeks ago - BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States - GlobeNewsWire
- 6 weeks ago - BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain - GlobeNewsWire
- 2 months ago - BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update - GlobeNewsWire
- 2 months ago - BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program - GlobeNewsWire